JAMA Network Home
Sign In
Editor's Pick Original Investigation

RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants

JAMA Pediatrics 10.1001/jamapediatrics.2026.4074

September 08, 2026 at 11:00 AM EDT

Read the full article

The results of this systematic review and meta-analysis suggest that postimplementation data support the effectiveness of RSVpreF in pregnancy for the prevention of RSV-associated LRTI hospitalization during the first 6 months of life. The results support the introduction of RSVpreF into routine antenatal immunization programs.

Authors examined 7 real-world studies in which maternal RSVpreF vaccination was associated with high effectiveness against RSV-associated lower respiratory tract infection hospitalization in infants during the first 6 months of life, particularly when given at least 14 days before delivery.

Corresponding Author: Bahaa Abu-Raya, MD, PhD, Canadian Center for Vaccinology, 5980 University Ave, Ste 5850, Room R4019, Halifax, NS B3K 6R8, Canada (bahaa.aburaya@dal.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.4074?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090826

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks